The tumor necrosis factor- (TNF-) antagonists infliximab, adalimumab, and etanercept have
The tumor necrosis factor- (TNF-) antagonists infliximab, adalimumab, and etanercept have already been approved for the treating chronic inflammatory diseases such as for example arthritis rheumatoid, ankylosing spondylitis, psoriasis, and psoriatic arthritis. symptoms, a therapy with tumor necrosis aspect- (TNF-) antagonists was initiated. Both subcutaneous etanercept at a dosage of 2 25 mg/week over six … [Read more…]